Icariin attenuates thioacetamide‑induced bone loss via the RANKL‑p38/ERK‑NFAT signaling pathway

Cheng,Linyan; Jin,Xiaoli; Shen,Hao; Chen,Xuanwei; Chen,Jin; Xu,Bin; Xu,Jian

doi:10.3892/mmr.2022.12642

Icariin attenuates thioacetamide‑induced bone loss via the RANKL‑p38/ERK‑NFAT signaling pathway

Authors:
- Linyan Cheng
- Xiaoli Jin
- Hao Shen
- Xuanwei Chen
- Jin Chen
- Bin Xu
- Jian Xu
View Affiliations

Affiliations: School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China
Published online on: February 14, 2022 https://doi.org/10.3892/mmr.2022.12642
Article Number: 126
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is an increasing incidence of destructive bone disease caused by osteoclast proliferation. This is characterized by reduced bone mass and imbalance of bone homeostasis. Icariin (ICA), a flavonoid compound isolated from Epimedium, has anti‑osteoporosis activity and inhibits the formation of osteoclasts and bone resorption. The purpose of the present study was to investigate the protective effect of ICA on osteoclastic differentiation induced by thioacetamide (TAA) and its possible mechanism in Sprague Dawley (SD) rats. In the present study, SD rats were intraperitoneally injected with TAA (300 mg/kg) for the bone loss model, treated with ICA (600 mg/kg, intragastric gavage) in the ICA group and TAA+ICA group for treatment of bone loss for 6 weeks. Indexes associated with bone metabolism, such as alkaline phosphatase, N‑terminal telopeptide of type‑I collagen (NTX‑I), calcium (Ca), phosphorus (P) and magnesium (Mg) in the serum, were detected. Osteoclast differentiation of femoral tissues was detected by hematoxylin and eosin and tartrate‑resistant acid phosphatase staining. The femoral bone mass was evaluated using a three‑point bending test and micro computed tomography. Western blotting was used to detect the expression levels of osteoclast‑related proteins in each group. In the rats treated with TAA, the serum concentrations of Ca, P and Mg were decreased, the serum concentration of NTX‑I was increased, osteoclast differentiation of the femur was increased, femur bone stress and bone mass were decreased and the bone loss and osteoclast formation were reduced after ICA treatment. In addition, ICA inhibited the protein expression of receptor activator of nuclear factor κ‑Β ligand (RANKL), receptor activator of nuclear factor κ‑B (RANK), p38, ERK, c‑Fos and nuclear factor of activated T cells 1 (NFATc1) in the femur of rats treated with TAA. The results suggested that ICA may inhibit osteoclast differentiation by downregulating the RANKL‑p38/ERK‑NFAT signaling pathway and prevent TAA‑induced bone loss. The results are helpful to understand the mechanism of osteoclast differentiation induced by TAA, as well as the antiresorptive activity and molecular mechanism of ICA, and to provide new ideas for the treatment of osteolytic diseases.

View Figures

View References

1	Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, et al: Interim report and recommendations of the world health organization task-force for osteoporosis. Osteoporosis Int. 10:259–264. 1999. View Article : Google Scholar : PubMed/NCBI
2	Bawa S: The significance of soy protein and soy bioactive compounds in the prophylaxis and treatment of osteoporosis. J Osteoporosis. 2010:8910582010. View Article : Google Scholar : PubMed/NCBI
3	Kenkre JS and Bassett J: The bone remodelling cycle. Ann Clin Biochem. 55:308–327. 2018. View Article : Google Scholar : PubMed/NCBI
4	Huang YY, Wang ZH, Deng LH, Wang H and Zheng Q: Oral administration of quercetin or its derivatives inhibit bone loss in animal model of osteoporosis. Oxid Med Cell Longev. 2020:1–21. 2020. View Article : Google Scholar
5	Tanaka S: RANKL-Independent osteoclastogenesis: A long-standing controversy. J Bone Miner Res. 32:431–433. 2017. View Article : Google Scholar : PubMed/NCBI
6	Liu Z, Zhang M, Shen Z, Ke J, Zhang D and Yin F: Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials. PLoS One. 15:e02438512020. View Article : Google Scholar : PubMed/NCBI
7	Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP and Lindsay RL: Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 10:796–802. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ma XQ, Han T, Zhang X, Wu JZ, Rahman K, Qin LP and Zheng CJ: Kaempferitrin prevents bone lost in ovariectomized rats. Phytomedicine. 22:1159–1162. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hwang YH, Ha H, Kim R, Cho CW, Song YR, Hong HD and Kim T: Anti-osteoporotic effects of polysaccharides isolated from persimmon leaves via osteoclastogenesis inhibition. Nutrients. 10:9012018. View Article : Google Scholar : PubMed/NCBI
10	Zhang Z, Zhao Q, Liu T, Zhao H, Wang R, Li H, Zhang Y, Shan L, He B, Wang X, et al: Effect of Vicenin-2 on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 129:1104742020. View Article : Google Scholar : PubMed/NCBI
11	Topolska K, Radzki RP, Filipiak-Florkiewicz A, Florkiewicz A, Leszczyńska T and Cieślik E: Fructan-enriched diet increases bone quality in female growing rats at calcium deficiency. Plant Foods Hum Nutr. 73:172–179. 2018. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Chen J, Chen J, Dong C, Yan X, Zhu Z, Lu P, Song Z, Liu H and Chen S: Daphnetin ameliorates glucocorticoid-induced osteoporosis via activation of Wnt/GSK-3β/β-catenin signaling. Toxicol Appl Pharm. 409:1153332020. View Article : Google Scholar : PubMed/NCBI
13	Komori T: Animal models for osteoporosis. Eur J Pharmacol. 759:287–294. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lassila V and Virtanen P: Influence of experimental liver injury on rat blood and alveolar bone under stress. Acta Anat (Basel). 118:116–121. 1984. View Article : Google Scholar : PubMed/NCBI
15	Yao YT, Lu XR, Li Y, Zhou YK, Ren J and Xu J: The new toxic effect of cortical bone osteoporosis induced by thioacetamide. J Toxicol. 33:370–374. 2019.
16	Liang X, Hou Z, Xie Y, Yan F, Li S, Zhu X and Cai L: Icariin promotes osteogenic differentiation of bone marrow stromal cells and prevents bone loss in OVX mice via activating autophagy. J Cell Biochem. 120:13121–13132. 2019. View Article : Google Scholar : PubMed/NCBI
17	Wang GQ, Li DD, Huang C, Lu DS, Zhang C, Zhou S, Liu J and Zhang F: Icariin reduces dopaminergic neuronal loss and microglia-mediated inflammation in vivo and in vitro. Front Mol Neurosci. 10:4412018. View Article : Google Scholar : PubMed/NCBI
18	Song L, Chen X, Mi L, Liu C, Zhu S, Yang T, Luo X, Zhang Q, Lu H and Liang X: Icariin-induced inhibition of SIRT6/NF-κB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer. Cancer Sci. 111:4242–4256. 2020. View Article : Google Scholar : PubMed/NCBI
19	Nian H, Ma MH, Nian SS and Xu LL: Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine. 16:320–326. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Tao Y, Ping Z, Zhang W, Hu X, Wang Y, Wang L, Shi J, Wu X, Yang X, et al: Icariin attenuates titanium-particle inhibition of bone formation by activating the Wnt/β-catenin signaling pathway in vivo and in vitro. Sci Rep. 6:238272016. View Article : Google Scholar : PubMed/NCBI
21	Kim B, Lee KY and Park B: Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells. Phytomedicine. 51:181–190. 2018. View Article : Google Scholar : PubMed/NCBI
22	Jing X, Du T, Chen K, Guo J, Xiang W, Yao X, Sun K, Ye Y and Guo F: Icariin protects against iron overload-induced bone loss via suppressing oxidative stress. J Cell Physiol. 234:10123–10137. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hassanshahi M, Su YW, Khabbazi S, Fan CM, Tang Q, Wen X, Fan J, Chen KM and Xian CJ: Icariin attenuates methotrexate chemotherapy-induced bone marrow microvascular damage and bone loss in rats. J Cell Physiol. 234:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
24	Schyman P, Printz RL, Estes SK, Boyd KL, Shiota M and Wallqvist A: Identification of the toxicity pathways associated with thioacetamide-induced injuries in rat liver and kidney. Front Pharmacol. 9:12722018. View Article : Google Scholar : PubMed/NCBI
25	Nakano A, Kanda T and Abe H: Bone changes and mineral metabolism disorders in rats with experimental liver cirrhosis. J Gastroenterol Hepatol. 11:1143–1154. 1997. View Article : Google Scholar : PubMed/NCBI
26	El-Shwiniy WH and Sadeek SA: Synthesis and characterization of new 2-cyano-2-(p-tolyl-hydrazono)-thioacetamide metal complexes and a study on their antimicrobial activities. Spectrochimica Acta A Mol Biomol Spectrosc. 137:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
27	Gao M, Wang M and Zheng QH: Synthesis of carbon-11-labeled imidazopyridine- and purine-thioacetamide derivatives as new potential PET tracers for imaging of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1). Bioorg Med Chem Lett. 26:1371–1375. 2016. View Article : Google Scholar : PubMed/NCBI
28	Khattab A, Hassanin L and Zaki N: Self-nanoemulsifying drug delivery system of coenzyme (Q10) with improved dissolution, bioavailability, and protective efficiency on liver fibrosis. AAPS PharmSciTech. 18:1657–1672. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhang Y, Han B, Wei Y, Jing J and Li J: Icariin promotes fracture healing in ovariectomized rats. Med Sci Monit. 26:e9245542020. View Article : Google Scholar : PubMed/NCBI
30	Clark JA and Sun D: Guidelines for the ethical review of laboratory animal welfare People's Republic of China National Standard GB/T 35892-2018 [Issued 6 February 2018 Effective from 1 September 2018]. Animal Model Exp Med. 3:103–113. 2020. View Article : Google Scholar : PubMed/NCBI
31	Zeng Q, Lu W, Deng Z, Wu J and Xu X: Tablysin-15 inhibits osteoclastogenesis and LPS-induced bone loss via attenuating the integrin αvβ3 pathway. Chem Biol Interact. 327:1091792020. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Chen Z, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T and Matsuo K: Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metabolism. 4:111–121. 2006. View Article : Google Scholar : PubMed/NCBI
34	Armas LA and Recker RR: Pathophysiology of osteoporosis: New mechanistic insights. Endocrinol Metab Clin North Am. 41:475–486. 2012. View Article : Google Scholar : PubMed/NCBI
35	Virtanen P and Lassila V: Influence of thioacetamide-provoked liver injury on female rat blood and alveolar bone under stress. Acta Anat (Basel). 127:285–289. 1986. View Article : Google Scholar : PubMed/NCBI
36	Qi S, He J, Zheng H, Chen C and Lan S: Icariin prevents diabetes-induced bone loss in rats by reducing blood glucose and suppressing bone turnover. Molecules. 24:18712019. View Article : Google Scholar : PubMed/NCBI
37	Cui J, Zhu M, Zhu S, Wang G, Xu Y and Geng D: Inhibitory effect of icariin on Ti-induced inflammatory osteoclastogenesis. J Surg Res. 192:447–453. 2014. View Article : Google Scholar : PubMed/NCBI
38	Liu CT, Shivani S, Xu H, McLean RR, Broe KE, Hannan MT, Boyd SK, Bouxsein ML, Kiel DP and Samelson EJ: Long-term and recent weight change are associated with reduced peripheral bone density, deficits in bone microarchitecture, and decreased bone strength: The framingham osteoporosis study. J Bone Miner Res. 33:1851–1858. 2018. View Article : Google Scholar : PubMed/NCBI
39	Oršolić N, Nemrava J, Jeleč Ž, Kukolj M, Odeh D, Terzić S, Fureš R, Bagatin T and Bagatin D: The beneficial effect of proanthocyanidins and icariin on biochemical markers of bone turnover in rats. Int J Mol Sci. 19:27462018. View Article : Google Scholar : PubMed/NCBI
40	Zhang J, Fu Q, Ren Z, Wang Y, Wang C, Shen T, Wang G and Wu L: Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol. 31:183–190. 2014. View Article : Google Scholar : PubMed/NCBI
41	Yang W, Zhang Y, Yang J, Tan L and Yang K: Potential antiosteoporosis effect of biodegradable magnesium implanted in STZ-induced diabetic rats. J Biomed Mater Res A. 99:386–394. 2011. View Article : Google Scholar : PubMed/NCBI
42	Jing Z, Wang C, Yang Q, Wei X, Jin Y, Meng Q, Liu Q, Liu Z, Ma X, Liu K, et al: Luteolin attenuates glucocorticoid-induced osteoporosis by regulatingERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. J Cell Physiol. 234:4472–4490. 2019. View Article : Google Scholar : PubMed/NCBI
43	Dénarié D, Constant E, Thomas T and Marotte H: Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? Mediators Inflamm. 2014:5373242014. View Article : Google Scholar : PubMed/NCBI
44	Feng M, Zhang RR, Gong F, Yang P, Fan L, Ni J, Bi W, Zhang Y, Wang C and Wang K: Protective effects of necrostatin-1 on glucocorticoid-induced osteoporosis in rats. J Steroid Biochem Mol Biol. 144:455–462. 2014. View Article : Google Scholar : PubMed/NCBI
45	Liu X, Fan JB, Hu J, Li F, Yi R, Tan F and Zhao X: Lactobacillus Fermentum ZS40 prevents secondary osteoporosis in wistar rat. Food Sci Nutr. 8:5182–5191. 2020. View Article : Google Scholar : PubMed/NCBI
46	Xu H, Zhou S, Qu R, Yang Y, Gong X, Hong Y, Jin A, Huang X, Dai Q and Jiang L: Icariin prevents oestrogen deficiency-induced alveolar bone loss through promoting osteogenesis via STAT3. Cell Prolif. 53:e127432020. View Article : Google Scholar : PubMed/NCBI
47	Huang M, Wang Y and Peng R: Icariin alleviates glucocorticoid-induced osteoporosis through EphB4/Ephrin-B2 axis. Evid Based Complement Alternat Med. 2020:29824802020. View Article : Google Scholar : PubMed/NCBI
48	Guo J, Ren R, Sun K, Yao X, Lin J, Wang G, Guo Z, Xu T and Guo F: PERK controls bone homeostasis through the regulation of osteoclast differentiation and function. Cell Death Dis. 11:8472020. View Article : Google Scholar : PubMed/NCBI
49	Boyce BF: Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 92:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
50	Chen KM, Ge BF, Liu XY, Ma PH, Lu MB, Bai MH and Wang Y: Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie. 62:388–391. 2007.PubMed/NCBI
51	Feng R, Feng L, Yuan Z, Wang D, Wang F, Tan B, Han S, Li T, Li D and Han Y: Icariin protects against glucocorticoid-induced osteoporosis in vitro and prevents glucocorticoid-induced osteocyte apoptosis in vivo. Cell Biochem Biophys. 67:189–197. 2013. View Article : Google Scholar : PubMed/NCBI